Title: Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national
retrospective multicentric study from the Brazilian Study Group of IBD (GEDIIB)
Version: 4 Date: 28 Apr 2022
Reviewer's report:
The authors have revised this article, but the following concern remains unaddressed.
-The authors need to change the inclusion criteria according to the primary outcome, whether
they want to understand the actual situation in Brazil or whether they want to see a change in
UC activity with the use of TNF-a agents.  When they assess the safety of anti-TNF in Brazil,
they can include all patients. However, as the primary outcome is to evaluate the efficacy,  they
should include only active UC patients without EIM.
-In Figure 1, adding the number of patients at each time point is able to make it easier to
understand.
Title: Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national
retrospective multicentric study from the Brazilian Study Group of IBD (GEDIIB)
Version: 4 Date: 28 Apr 2022
Reviewer's report:
The authors have revised this article, but the following concern remains unaddressed.
-The authors need to change the inclusion criteria according to the primary outcome, whether
they want to understand the actual situation in Brazil or whether they want to see a change in
UC activity with the use of TNF-a agents.  When they assess the safety of anti-TNF in Brazil,
they can include all patients. However, as the primary outcome is to evaluate the efficacy,  they
should include only active UC patients without EIM.
-In Figure 1, adding the number of patients at each time point is able to make it easier to
understand.
Please review this paper.
user
Title: Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national
retrospective multicentric study from the Brazilian Study Group of IBD (GEDIIB)
Version: 4 Date: 28 Apr 2022
Reviewer's report:
The authors have revised this article, but the following concern remains unaddressed.
-The authors need to change the inclusion criteria according to the primary outcome, whether
they want to understand the actual situation in Brazil or whether they want to see a change in
UC activity with the use of TNF-a agents.  When they assess the safety of anti-TNF in Brazil,
they can include all patients. However, as the primary outcome is to evaluate the efficacy,  they
should include only active UC patients without EIM.
-In Figure 1, adding the number of patients at each time point is able to make it easier to
understand.
assistant